The latest price target for Viridian Therapeutics (NASDAQ:VRDN) was reported by RBC Capital on September 19, 2024. The analyst firm set a price target for $44.00 expecting VRDN to rise to within 12 months (a possible 107.65% upside). 34 analyst firms have reported ratings in the last year.

The latest analyst rating for Viridian Therapeutics (NASDAQ:VRDN) was provided by RBC Capital, and Viridian Therapeutics reiterated their outperform rating.

There is no last upgrade for Viridian Therapeutics

The last downgrade for Viridian Therapeutics Inc happened on May 9, 2024 when Ladenburg Thalmann changed their price target from N/A to N/A for Viridian Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viridian Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viridian Therapeutics was filed on September 19, 2024 so you should expect the next rating to be made available sometime around September 19, 2025.

While ratings are subjective and will change, the latest Viridian Therapeutics (VRDN) rating was a reiterated with a price target of $44.00 to $44.00. The current price Viridian Therapeutics (VRDN) is trading at is $21.19, which is out of the analyst’s predicted range.